The global EYLEA drug market comprises medications used for treating various ocular disorders such as wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and macular edema following retinal vein occlusion. EYLEA (aflibercept) drug is a vascular endothelial growth factor (VEGF) inhibitor used for wet AMD treatment approved by Food and Drug Administration (FDA) in 2011. It prevents growth of new blood vessels and leakage that can lead to vision loss. The drug also prevents further progression of the ocular disease.

The Global EYLEA Drug Market Size Is Estimated To Be Valued At US$ 8.79 Bn In 2024 And Is Expected To Exhibit A CAGR Of 7.2% Over The Forecast Period 2024-2031.

Key Takeaways

Key players operating in the global EYLEA drug market are Bayer, Regeneron Pharmaceuticals, Coherus Biosciences, Inc., And Klinge Biopharma. Bayer And Regeneron Pharmaceuticals Currently Dominate The Market With Their Product EYLEA. Coherus BioSciences also gained FDA approval for its aflibercept biosimilar referred as Zyla in 2021. Growing prevalence of retinal disorders such as AMD, DR and increasing patient diagnosis rate are expected to drive the market growth during the forecast period. Technological advancements in intravitreal injections and rise of biosimilars for affordable treatment options will further support the market expansion.

Market Trends

One of the key trends in the EYLEA drug market is rising adoption of monoclonal antibody therapies globally for treatment of various ocular diseases. EYLEA acts as VEGF inhibitor that helps prevent diseases progression with minimal side effects. Secondly, advancements in intravitreal injection devices and techniques have made in-office treatment simpler and less discomforting for patients.

Market Opportunities

Increasing healthcare spending in emerging economies and rise of medical tourism will drive the EYLEA drug market growth in coming years. Secondly, expansion of key players in untapped markets through strategic collaborations will further create market opportunities between 2024-2031.

Impact Of COVID-19 On The Global EYLEA Drug Market

The COVID-19 pandemic has impacted the growth of the global EYLEA drug market. During the initial phase of the pandemic in 2020, eye care facilities witnessed a decline in patient visits and treatment procedures due to lockdowns and restrictions imposed to curb the virus spread. This led to a reduced demand for EYLEA drugs in the short run. However, with the development of vaccines and initiation of vaccination programs, eye care services are returning to pre-pandemic levels. This is expected to drive the growth of the EYLEA drug market in the coming years.

Manufacturers are focusing on ensuring continuous supply of EYLEA drugs during the pandemic period to cater to critical eye diseases. They are adopting safety measures across production and distribution facilities. Teleophthalmology and telemedicine also gained prominence during this time to provide remote consultation and treatment to patients. This helped in timely diagnosis and management of eye diseases. With economic recovery underway in 2022, healthcare spending is projected to rise globally which will support the market growth.

The United States accounts for the major share of the global EYLEA drug market in terms of value. This is attributed to the growing prevalence of eye diseases, large patient population undergoing treatment, and high affordability for expensive biologics in the country. Within the US, market revenue is concentrated in States like California, New York, Texas, and Florida owing to their large economies and populations. Europe is the second largest regional market led by countries such as Germany, France, Italy, and the UK. Asia Pacific region is emerging as the fastest growing market for EYLEA drugs on account of rising healthcare investment, increasing incidence of diabetic retinopathy, and growing medical tourism in countries like China, India and South Korea.

The global EYLEA drug market was concentrated majorly in the United States and key European countries prior to the pandemic in terms of revenue generation. However, post COVID, the Asia Pacific region especially China and India are projecting fast market growth on back of their large populations, economic development and focus on preventing blindness. Moreover, these nations are witnessing increasing healthcare expenditure and prevalence of retinal disorders which is contributing to sustained rise in EYLEA drug demand. The market in Asia Pacific is projected to witness the highest CAGR during the forecast period from 2024 to 2031.

Impact Of COVID-19 On The Global EYLEA Drug Market

The COVID-19 pandemic initially disrupted the growth of the global EYLEA drug market in 2020 due to lockdowns and restrictions imposed worldwide. This led to declined patient footfall and treatment procedures across ophthalmology facilities globally. However, with vaccination programs underway, eye care services are returning to pre-COVID levels and this will support market prospects. During the pandemic, manufacturers ensured adequate supply of EYLEA drugs and adopted safety measures. Telehealth also aided timely diagnosis and management of retinal disorders. Economic recovery is further driving healthcare spending which will fuel market growth in the coming years.

The United States accounts for the major market share led by disease burden, affordability and large population concentrated in States like California, New York, Texas and Florida. Europe trails behind led by key markets of Germany, France, Italy and the UK. However, post COVID, Asia Pacific region especially China and India are emerging as fastest growing markets on account of rising income levels, healthcare investments, focus on blindness prevention and growing geriatric populations prone to retinal disorders. The market in Asia Pacific will witness the highest growth rate during the forecast period from 2024 to 2031.

What are the key data covered in this Global EYLEA Drug Market report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Global EYLEA Drug Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Global EYLEA Drug Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behavior

:- Global EYLEA Drug Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Global EYLEA Drug Market vendors

FAQ’s

Q.1 What are the main factors influencing the Global EYLEA Drug market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Global EYLEA Drug Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Global EYLEA Drug market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?

Get more insights on this topic: https://www.pressreleasebulletin.com/global-eylea-drug-market-trend-size-and-demand/